Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
8 participants
INTERVENTIONAL
2020-03-01
2021-08-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma
NCT03772756
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
NCT05723107
EUS-guided RFA for Pancreatic Neoplasms
NCT03218345
Ex-vivo Ultrasound Guided Radiofrequency Ablation on Pancreatic Solid Lesions
NCT06371716
EUS-RFA PANCARDINAL-1 Trial
NCT04990609
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EUS-RFA
Patients were placed in the lateral position under deep sedation with supplementary oxygen and electrocardiograph monitoring. The target tumor was identified by EUS, then the biopsy needle stylet was removed and replace with the RFA probe. RF energy was applied for 90-120 seconds at 5 Watts. Wait 1 minute before repositioning the Habib™ EUS RFA needle and repeat procedure as many times as needed to ensure complete ablation of the tumor. EUS-guided celiac plexus neurolysis (EUS-CPN) was performed on patients with intractable upper abdominal pain.
EUS-RFA
Use EUS-RFA to treat unresectable pancreatic cancer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EUS-RFA
Use EUS-RFA to treat unresectable pancreatic cancer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First People's Hospital of Hangzhou
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jianfeng Yang
Associate director of gastroenterology department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaofeng Zhang, M.S
Role: PRINCIPAL_INVESTIGATOR
First People's Hospital of Hangzhou
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-01-112
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.